Disease · MONDO_0019623
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| KALBITOR (Ecallantide) vs Placebo: Patients With Significant Improvement in Overall Response | 22 of 48 | 12 of 48 | 96 | NCT00457015 | Trial comparisons |
| KALBITOR (Ecallantide) vs Placebo: serious adverse events | 0 of 48 | 3 of 48 | 96 | NCT00457015 | Trial comparisons |
| KALBITOR (Ecallantide) vs Placebo: Proportion of Patients Maintaining a Significant Improvement in Overall Response Through 24 Hours | 21 of 48 | 10 of 47 | 95 | NCT00457015 | Trial comparisons |
| KALBITOR (Ecallantide) vs Placebo: Patients With a Successful Response at 4 Hours Post-dosing, Based on the Change From Baseline in the MSCS Score | 45 of 48 | 28 of 47 | 95 | NCT00457015 | Trial comparisons |
| C1INH-nf vs Placebo: serious adverse events | 0 of 71 | 0 of 12 | 83 | NCT00289211 | Trial comparisons |
| rhC1INH vs Placebo (Saline): serious adverse events | 1 of 56 | 0 of 18 | 74 | NCT01188564 | Trial comparisons |
| C1INH-nf vs Placebo: Number of Subjects With Beginning of Substantial Relief of the Defining Symptom | 21 of 35 | 14 of 33 | 68 | NCT00289211 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants With Adverse Events (AEs) | 2 of 11 | 11 of 21 | 32 | NCT01386658 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations | 0 of 11 | 0 of 21 | 32 | NCT01386658 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants With Clinically Significant Changes in Reproductive Hormones | 0 of 11 | 0 of 21 | 32 | NCT01386658 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants With Clinically Significant Changes in Vital Signs | 0 of 11 | 0 of 21 | 32 | NCT01386658 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants Who Reported Presence of Anti-icatibant Antibodies | 0 of 11 | 0 of 21 | 32 | NCT01386658 | Trial comparisons |
| Prepubertal vs Pubertal/Postpubertal: Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) | 0 of 11 | 0 of 21 | 32 | NCT01386658 | Trial comparisons |
| Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 vs SC CINRYZE With rHuPH20 Dose Level 2: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT01426763 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019623/comparisons